Portland Investment Counsel Inc. Takes $1.23 Million Position in Telix Pharmaceuticals Limited $TLX

Portland Investment Counsel Inc. purchased a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 128,000 shares of the company’s stock, valued at approximately $1,225,000. Telix Pharmaceuticals comprises approximately 0.3% of Portland Investment Counsel Inc.’s investment portfolio, making the stock its 28th largest position.

Several other hedge funds and other institutional investors have also made changes to their positions in TLX. Private Advisor Group LLC increased its holdings in Telix Pharmaceuticals by 67.3% in the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after purchasing an additional 16,945 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Telix Pharmaceuticals in the third quarter valued at about $243,000. Rhumbline Advisers boosted its holdings in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. IHT Wealth Management LLC bought a new position in Telix Pharmaceuticals during the second quarter worth about $213,000. Finally, Jane Street Group LLC acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth about $564,000.

Analyst Ratings Changes

TLX has been the subject of a number of recent analyst reports. Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Citigroup boosted their price objective on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $21.13.

Telix Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ TLX opened at $7.85 on Friday. The company has a fifty day moving average price of $7.32 and a 200 day moving average price of $8.82. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals Limited has a 1-year low of $6.28 and a 1-year high of $20.00.

Telix Pharmaceuticals (NASDAQ:TLX) last released its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). As a group, equities analysts expect that Telix Pharmaceuticals Limited will post 0.24 EPS for the current year.

Telix Pharmaceuticals Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.